SNN

Smith & Nephew plc Sponsored ADR (SNN) | Rumor.io

Smith & Nephew

SNN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,164

Bullish sentiment (50-day avg)36%

Price to earnings ratio18.3

Market capitalization11.3B

Earnings per share1.47

Dividend yield (TTM)3.56%

Revenue (annual)6.2B

Net income (annual)625M

Social

What share of all stock conversation is about SNN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% +0

Nov 13

The sentiment around $SNN is cautious due to tightening medical device regulations.
There are concerns that preterm labor drug regulations may be overvalued.
Investors are cautious about the impact of regulations on $SNN's sentiment.

Generated by AI

Sentiment

Of the messages about SNN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0% -100	48.28% +40.58	67.33% -18.72
Bearish	100%	100% new	51.72% -40.58	32.67% +18.72

Topics

Of the messages about SNN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	37.5%	53.93%
Analysts	0%	0%	0%	4.49%
Earnings	0%	0%	0%	0.37%
Technical Analysis	100%	100%	62.5%	37.83%
Controversies	0%	0%	0%	2.25%
Macro	0%	0%	0%	1.12%

Earnings· Nov 1

Smith & Nephew plc reported Q3 revenues of $1.169 billion, a 2% year-over-year increase.
The company's Q3 revenue figure matched the Capital IQ consensus estimate of $1.169 billion.
Smith & Nephew plc reaffirmed its full-year 2018 earnings guidance.

Analysts· Nov 1

Smith & Nephew plc has been given an overweight rating by Barclays, with the company ranked 21st in the list.
JPMorgan Chase & Co. has reaffirmed a neutral rating for Smith & Nephew plc, with the company ranked 33rd.
Morgan Stanley has reaffirmed an underweight rating for Smith & Nephew plc, with the company ranked 37th.

Announcements· Mar 12

Smith & Nephew ($SNN) acquires Osiris Therapeutics ($OSIR) for $19/share in cash, a 37% premium to the 90-day volume-weighted average price.
The acquisition is valued at $660M and expands Smith & Nephew's presence in the high growth regenerative medicine market.
NuVasive ($NUVA) is down 7% following the announcement, as it was rumored to be a potential target for Smith & Nephew.

Generated by AI

Community

Of the messages about SNN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25%	25%	38.89%	6.36%
Newcomers	75%	75%	61.11%	93.64%

Regulars· Feb 20

Sunniva Inc. is facing liquidity issues and has announced the resignation of a board member, which may impact its current financial situation.
Smith & Nephew's FY results beat expectations, with EPS in-line and revenue growth at the top end of the range, contributing to a +6% premarket gain.
Smith & Nephew has declared a dividend of $0.462, and its Q4 results showed revenue growth at the top end of the range, with a new 52-week high set at $52.00.

Newcomers· Nov 13

Newcomers to the stock are expressing caution about the tightening of medical device regulations, which they believe may impact $SNN's sentiment.
Some newcomers think that the preterm labor drug regulations are overvalued and may not be a good investment opportunity for $SNN.
The newcomers are also concerned that the tightening of medical device regulations may lead to a cautious sentiment around $SNN.

Generated by AI

The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted choice for traum

6d agoYahoo Finance

Smith & Nephew stock hits 52-week low at 27.05 USD

6d agoInvesting.com

Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S. Food and Drug A...

8d agomarkets.businessinsider.com

Smith & Nephew fined £230k after delivery driver seriously hurt

The penalty comes after a man suffered life-changing injuries when a crate fell on him.

13d agoBBC

Smith & Nephew Accepts $250 Million of 2030 Notes in Tender Offer

Smith & Nephew (SNN) accepted $250 million of its 2.032% senior notes due 2030 in a cash tender offe

14d agoYahoo Finance

Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the results of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to

14d agoYahoo Finance

Also Discussed

Investors talking about SNN also mention

#	Name	Attention
1	Royal Gold, Inc.RGLD	0%+0
2	Stryker CorporationSYK	0.01%+0.01
3	FlexShares Morningstar U.S. Market Factor Tilt ETFTILT	0%0
4	Virtus Seix AAA Private Credit CLO ETFPCLO	0%new
5	Zimmer Biomet Holdings, Inc.ZBH	0%0
6	MiMedx Group, Inc.MDXG	0%0
7	Perrigo Company plcPRGO	0%0
8	Stabilis Solutions Inc.SLNG	0%0
9	CONMED CorporationCNMD	0%new
10	Becton, Dickinson and CompanyBDX	0%0

Smith & Nephew plc Sponsored ADR

Healthcare
Medical Devices

Smith & Nephew plc Sponsored ADR is a healthcare equipment and medical technology company focused on developing, manufacturing, and marketing devices used in orthopaedics, sports medicine, ENT, and advanced wound management. Smith & Nephew supports surgical care and patient recovery through products and services for joint repair and replacement, trauma treatment, minimally invasive procedures, robotics-enabled surgery, and wound healing. Its portfolio serves hospitals, ambulatory surgery centers, and other healthcare providers across international markets, making the company an important supplier within the global medical device industry. Smith & Nephew’s current business is centered on solutions that help clinicians improve procedural efficiency, tissue repair, and post-operative care in a wide range of specialties.

Website

Location

Building 5

Watford, WD18 8YE

United Kingdom

Social

What share of all stock conversation is about SNN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% +0

Nov 13

The sentiment around $SNN is cautious due to tightening medical device regulations.
There are concerns that preterm labor drug regulations may be overvalued.
Investors are cautious about the impact of regulations on $SNN's sentiment.

Generated by AI

Sentiment

Of the messages about SNN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0% -100	48.28% +40.58	67.33% -18.72
Bearish	100%	100% new	51.72% -40.58	32.67% +18.72

Topics

Of the messages about SNN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	37.5%	53.93%
Analysts	0%	0%	0%	4.49%
Earnings	0%	0%	0%	0.37%
Technical Analysis	100%	100%	62.5%	37.83%
Controversies	0%	0%	0%	2.25%
Macro	0%	0%	0%	1.12%

Earnings· Nov 1

Smith & Nephew plc reported Q3 revenues of $1.169 billion, a 2% year-over-year increase.
The company's Q3 revenue figure matched the Capital IQ consensus estimate of $1.169 billion.
Smith & Nephew plc reaffirmed its full-year 2018 earnings guidance.

Analysts· Nov 1

Smith & Nephew plc has been given an overweight rating by Barclays, with the company ranked 21st in the list.
JPMorgan Chase & Co. has reaffirmed a neutral rating for Smith & Nephew plc, with the company ranked 33rd.
Morgan Stanley has reaffirmed an underweight rating for Smith & Nephew plc, with the company ranked 37th.

Announcements· Mar 12

Smith & Nephew ($SNN) acquires Osiris Therapeutics ($OSIR) for $19/share in cash, a 37% premium to the 90-day volume-weighted average price.
The acquisition is valued at $660M and expands Smith & Nephew's presence in the high growth regenerative medicine market.
NuVasive ($NUVA) is down 7% following the announcement, as it was rumored to be a potential target for Smith & Nephew.

Generated by AI

Community

Of the messages about SNN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25%	25%	38.89%	6.36%
Newcomers	75%	75%	61.11%	93.64%

Regulars· Feb 20

Sunniva Inc. is facing liquidity issues and has announced the resignation of a board member, which may impact its current financial situation.
Smith & Nephew's FY results beat expectations, with EPS in-line and revenue growth at the top end of the range, contributing to a +6% premarket gain.
Smith & Nephew has declared a dividend of $0.462, and its Q4 results showed revenue growth at the top end of the range, with a new 52-week high set at $52.00.

Newcomers· Nov 13

Newcomers to the stock are expressing caution about the tightening of medical device regulations, which they believe may impact $SNN's sentiment.
Some newcomers think that the preterm labor drug regulations are overvalued and may not be a good investment opportunity for $SNN.
The newcomers are also concerned that the tightening of medical device regulations may lead to a cautious sentiment around $SNN.

Generated by AI

Smith & Nephew

Social

Nov 13

Sentiment

Topics

Earnings· Nov 1

Analysts· Nov 1

Announcements· Mar 12

Community

Regulars· Feb 20

Newcomers· Nov 13

News

Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

Smith & Nephew stock hits 52-week low at 27.05 USD

Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System

Smith & Nephew fined £230k after delivery driver seriously hurt

Smith & Nephew Accepts $250 Million of 2030 Notes in Tender Offer

Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

Also Discussed

Smith & Nephew plc Sponsored ADR

Company Information

Location

News

Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

Smith & Nephew stock hits 52-week low at 27.05 USD

Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System

Smith & Nephew fined £230k after delivery driver seriously hurt

Smith & Nephew Accepts $250 Million of 2030 Notes in Tender Offer

Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

Also Discussed

Social

Nov 13

Sentiment

Topics

Earnings· Nov 1

Analysts· Nov 1

Announcements· Mar 12

Community

Regulars· Feb 20

Newcomers· Nov 13